AMGN compared with TSHA: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

TSHATaysha Gene Therapies, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

TSHATaysha Gene Therapies, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±3.7%▲+3.73%×1.00

Q2 FY26±4.1%▲+4.57%×1.12

Q1 FY26±3.9%▼−4.75%×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

TSHA

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.4%▼−4.12%×0.31

May 6 '26±14.4%▲+0.58%×0.04

= impliedAMGN realized, solidTSHA realized, hatchedOne scale, both sides: full bar = 23%× = |realized| ÷ impliedSource: market data

Q1 FY26

±12.0%

▲+2.47%

×0.21

Q3 FY25±22.5%▼−4.26%×0.19

AMGNAmgen Inc

460.55▲+0.06%· post 460.42

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

TSHATaysha Gene Therapies, Inc.

4.33▲+5.87%· post 4.33

ClosedNov 6 '26

Mkt cap$1.4BRevenue$5MQ4 FY25Revenue$8MFY24

Compare

ClosedNov 6 '26

AMGNAmgen Inc

TSHATaysha Gene Therapies, Inc.

460.55▲+0.06%post 460.42

Price

4.33▲+5.87%post 4.33

$249.0B

Mkt cap

$1.4B

Q3 FY26$10.4B

Revenue

$5MQ4 FY25

FY25$36.8B

Revenue

$8MFY24

AMGN460.55▲+0.06%vsTSHA4.33▲+5.87%ClosedNov 6 '26